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Available online 4 June 2013Anti-angiogenic and anti-lymphangiogenic drugs slow tumor progression and dissemination. However, an
important difﬁculty is that a tumor reacts and compensates to obtain the blood supply needed for tumor
growth and lymphatic vessels to escape to distant loci. Therefore, there is a growing consensus on the
requirement of multiple anti-(lymph)angiogenic molecules to stop cell invasion efﬁciently.
Here we studied the cooperation between endogenous anti-angiogenic molecules, endostatin and ﬁbstatin, and a
chemokine, the Platelet Factor-4 variant 1, CXCL4L1. Anti-angiogenic factors were co-expressed by IRES-based
bicistronic vectors and their cooperationwas analyzed either by local delivery following transduction of pancreatic
adenocarcinoma cells with lentivectors, or by distant delivery resulting from intramuscular administration in vivo
of adeno-associated virus derived vectors followed by tumor subcutaneous injection. In this study, ﬁbstatin and
CXCL4L1 cooperate to inhibit endothelial cell proliferation, migration and tubulogenesis in vitro. No synergistic
effect was found for ﬁbstatin–endostatin combination. Importantly, we demonstrated for the ﬁrst time that
ﬁbstatin and CXCL4L1 not only inhibit in vivo angiogenesis, but also lymphangiogenesis and tumor spread to
the lymph nodes, whereas no beneﬁcial effect was found on tumor growth inhibition using molecule combina-
tions compared tomolecules alone. These data reveal the synergy of CXCL4L1 and ﬁbstatin in inhibition of tumor
angiogenesis, lymphangiogenesis and metastasis and highlight the potential of IRES-based vectors to develop
anti-metastasis combined gene therapies.
© 2013 Elsevier Inc. All rights reserved.Introduction
Angiogenesis promotes tumor growth, while both angiogenesis
and lymphangiogenesis facilitate tumor dissemination by enhancing
transport of tumor cells to new sites (Mumprecht and Detmar,
2009). Tumor spread is a leading cause of cancer-related mortality
and morbidity, and both tumor cell intrinsic and extrinsic factors can
promote tumor cells dissemination (Nagy et al., 2002; Skobe et al.,
2001; Stacker et al., 2001). Metastases can be detected in draining
lymph nodes and, for many tumors including pancreatic, breast cancer
and melanoma, progress from lymph nodes to distant sites (Garmy-
Susini et al., 2010; Renyi-Vamos et al., 2005). In the absence of
neovasculature, tumors remain dormant (Nierodzik and Karpatkin,
2006). Thus, novel antiangiogenic treatment strategies that controlPoulhes, BP 84225, 31432
Garmy-Susini).
rights reserved.tumor growth are under intense investigation. However, recent studies
have shown evidences that treatment with anti-angiogenic molecules
elicits malignant progression of tumors and accelerates metastasis
suggesting that tumor cells escape the anti-angiogenic therapy (Paez-
Ribes et al., 2009). As tumor progression is associated with expression
of increasing numbers of pro-angiogenic and lymphangiogenic factors,
the blockade of tumor invasionmay require several anti-(lymph)angio-
genic agents to simultaneously attack this multiple redundant process.
In this study, we analyzed the combined effect of endogenous anti-
angiogenic molecules endostatin, ﬁbstatin and CXCL4L1. Endostatin is
a proteolytic polypeptide derived from collagen XVIII (O'Reilly et al.,
1997), ﬁbstatin, a proteolytic polypeptide derived from ﬁbronectin
(Bossard et al., 2004), and CXCL4L1 (PF4V1) a chemokine, the product
of the human nonallelic variant gene of CXCL4 (PF4) (Dubrac et al.,
2010). Those anti-angiogenic molecules were chosen for their proper-
ties to inhibit angiogenesis by targeting different signaling pathways.
Endostatin interferes with vascular endothelial growth factor (VEGF)
signaling. Fibstatin speciﬁcally interacts with the angiogenic (and
lymphangiogenic) ﬁbroblast growth factor 2 (FGF2) (Bossard et al.,
26 A.C. Prats et al. / Microvascular Research 89 (2013) 25–332004). CXCL4L1 is a small inducible cytokine binding to G protein-
coupled receptors (GPCR) recently described as an anti-angiogenic
chemokine (Struyf et al., 2007).
To deliver combinedmolecules to tumor cells, we used gene transfer
vectors based on internal ribosome entry sites (IRESs). IRESs represent
useful tools to co-express combinations of two or more molecules in a
controlled ratio (Rayssac et al., 2009). We compared the effect of local
delivery (tumor cells transduced with lentivectors) or distant delivery
(intramuscular injection of recombinant adeno-associated virus
derived vectors, rAAV) to target both primary tumor and distant loci.
Our study shows a strong cooperative effect of ﬁbstatin and
CXCL4L1, but not of ﬁbstatin and endostatin in inhibition of endothelial
cell tubulogenesis, proliferation and migration in vitro as well as in the
blockade of tumoral angiogenesis in vivo. Interestingly, we demon-
strated for the ﬁrst time the anti-lymphangiogenic effect of ﬁbstatin
and CXCL4L1. Then, this study revealed the importance of ﬁbstatin
and CXCL4L1 synergistic cooperation on the inhibition of tumor spread.
Indeed, we obtained stronger effect with lower amount of proteins
using bicistronic vectors, the cooperative effect of ﬁbstatin and
CXCL4L1 was not observed on progression of the primary tumor, but
was signiﬁcant in inhibition of tumor invasion in lymph nodes.
Materials and methods
Mice study
Animal experiments were conducted in accordance with the
recommendations of the European Convention for the Protection of
Vertebrate Animals used for experimentation. All animal experiments
were performed according to the INSERM IACUC guidelines for labora-
tory animals' husbandry and have been approved by the local branch
Inserm Rangueil-Purpan of theMidi-Pyrénées ethics committee (proto-
col no. 088581114).
Lentivector construction and transduction
The cDNAs coding human endostatin,ﬁbstatin and CXCL4L1 (PF4V1),
were subcloned into the lentivector pTRIP-DU3-CMV-MCS derived from
the pTRIP-DU3-EF1a-EGFP (Sirven et al., 2001). The VEGF secretion
signal sequence and the HA tag were added to the N-terminal and
C-terminal, respectively, of endostatin and ﬁbstatin. The EF1a promoter
was replaced by the cytomegalovirus (CMV) promoter and a multiple
cloning site was inserted in place of the green ﬂuorescent protein
(GFP). This generated the monocistronic lentivectors pTRIP-ﬁbstatin,
-endostatin, and –CXCL4L1 respectively. To generate the bicistronic
lentivectors, the cDNAs were subcloned by pairs and separated by
the FGF1 IRES, resulting in the lentivectors pTRIP-ﬁbstatin-endostatin,
-ﬁbstatin-CXCL4L1 and -CXCL4L1-ﬁbstatin (Fig. 1). The six mono- or
bicistronic lentivectors were produced using the tri-transfection proce-
dure using the plasmids pLvPack and pLvVSVg (Sigma-Aldrich, Saint-
Quentin Fallavier, France), and were evaluated for their ability to
transduce pancreatic adenocarcinoma cell line (Capan-1). In each case,
GFP was used as a reporter transgene, and GFP FACS analysis was used
to visualize transduced cells in vitro (Suppl. Fig. 1).
A total of 6 × 105 Capan-1 cells were plated in 6-well plates and
transduced overnight in 1 mL of transduction medium (OptiMEM, Life
Technologies SAS, Saint Aubin, France) containing 6 μg/mL protamine
sulfate in the presence of puriﬁed lentiviral vector (MOI 0.8). Medium
was changed and cells were collected 48 h after transduction. EGFP-
positive cells were quantiﬁed by ﬂow cytometry analysis on FACScalibur
(Becton Dickinson SAS, Le Pont de Claix, France).
rAAV construction and transduction
The mono- and bicistronic cassettes coding the anti-angiogenic
factors described above were subcloned into the vector pAAV-MCS(Stratagene, Massy, France), resulting in three monocistronic recom-
binant adeno-associated viruses (rAAV): pAAV-endostatin, pAAV-
ﬁbstatin, pAAV-CXCL4L1; and two bicistronic rAAVs: pAAV-ﬁbstatin-
endostatin, pAAV-CXCL4L1-ﬁbstatin (Fig. 1). Serotype 1/2 rAAVs were
produced using the tri-transfection procedure using the plasmids
pHelper (Stratagene) and pDP1rs (Plasmidfactory), and injected in the
mice tibialis and gastrocnemius skeletal muscles. rAAV administration
to eachmouse (100 μL, 5.1011 pfu/mL)was divided into four injections:
20 μL were injected in each tibialis and 30 μL in each gastrocnemius.
rAAVs were evaluated for their ability to transduce mouse skeletal
muscle. As a control, we constructed and produced a bicistronic rAAV
expressing, under the control of theCMVpromoter, the renilla luciferase
and the ﬁreﬂy luciferase (Luc+) separated by the FGF1 IRES: pTRIP-
CRF1AL+. Fireﬂy luciferase immunohistological analysis was used to
visualize transduced cells in vivo (not shown).
Reagents
Recombinant human FGF-2 was from R&D Systems (Minneapolis,
MN). Rabbit anti-mouse Lyve-1 antibody (RDI-103PA50) was from
Research Diagnostics Incorporated (Concord, MA). Rat anti-mouse
CD31 (MEC 13.3) was from BD Bioscience (San Diego, CA). Goat anti-
PANCytokeratin,mouse anti-HA, donkey anti-rabbit and rat IgGs conju-
gated with DyLights Fluors 488, 568 were from TebuBio. Growth factor
depleted Matrigel was from Becton-Dickinson. Anti-human CXCL4
monoclonal antibody (mAb7952) is from R&D Systems (Minneapolis,
MN).
Cell culture
HUVECs (Promocell, Heidelberg, Germany) were cultured in
endothelial growth medium (EGM-2) containing 2% FBS (Promocell).
Capan-1 pancreatic ductal carcinoma cells were obtained from the NCI
ATCC and eachwas cultured in RPMI containing 10% FBS and antibiotics.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assays
HUVEC cells (2000 cells per well) were incubated in triplicate in a
96-well plate in the presence or absence of lentiviral-transduced cells
supernatants containing 10 ng/mL FGF2 for 48 h (R&D Systems,
Minneapolis, MN). The ability of anti-angiogenic molecules to suppress
cell growth was determined by MTT cell proliferation assays according
to manufacturer instructions (Sigma-Aldrich). Experiments were
performed three times in triplicate.
Migration assays
Conﬂuent HUVECs monolayers were scratched using a 20 μL
pipette tip. Plates were washed with PBS and incubated with lentiviral-
transduced cells supernatants containing 20 ng/mL FGF2 for 24 h.
Experiments were performed three times in triplicate.
Endothelial cell tubulogenesis assay in matrigel
HUVECs (5.104 cells)were added to 4wells chamber slides containing
300 μL Matrigel in the presence of capan-1 mono- and bicistronic
transuduced cells conditioned media containing 10 ng/ml FGF2. Cham-
ber slides were incubated at 37 °C for 24 h. The mean number of vessel
branch points +/−SEM was determined for triplicate samples. Experi-
ments were performed three times.
Immunohistochemistry
Tumors, draining (inguinal) lymph nodes and muscles were
embedded in OCT compound (Tissue-Tek; Sakura Finetek, Torrance,
Fig. 1. Combination of CXCL4L1 and ﬁbstatin inhibits angiogenesis in vitro. (A) Schematics of monocistronic and bicistronic expression cassettes subcloned into lentivectors and
rAAVs. The monocistronic cassettes code a single angiogenesis inhibitor (ﬁbstatin, endostatin or CXCL4L1) under control of the CMV promoter. Fibstatin and endostatin were
HA-tagged and contained the VEGF secretion signal sequence. Bicistronic vectors code two angiogenesis inhibitors whose sequences are separated by the FGF1 IRES. Three combi-
nations were designed: ﬁbstatin–endostatin, ﬁbstatin-CXCL4L1 and CXCL4L1–ﬁbstatin, respectively. (B) Western blot analysis of ﬁbstatin, endostatin and CXCL4L1 expression after
transduction of Capan-1 cells with mono- and bicistronic lentivectors. (B–D) Anti-angiogenic factor expression was evaluated on conditioned media after Capan-1 cell transduction
with ﬁbstatin, endostatin, or ﬁbstatin–endostatin (B); ﬁbstatin, CXCL4L1, and CXCL4L1–ﬁbstatin (C), or ﬁbstatin–CXCL4L1 (D) lentivectors. (E) Brightﬁeld images of HUVECs in vitro
after FGF2-stimulated endothelial cell tubulogenesis in matrigel in the presence of conditioned media from transduced Capan-1 cells. (F) Quantiﬁcation of tube formation mean
vessel branch points per 100× ﬁeld ± SEM. *p b 0.01, #p b 0.001.
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bodies. Blood and lymphatic vessel numbers were quantiﬁed in 5–10
microscopic ﬁelds per cryosection by automated pixel density deter-
mination as the mean number of vessels ± SEM for each treatment
group. The mean number of mice with metastases in inguinal (Capan-1)
lymph nodes was determined by immunostaining cryosections of nodes
with 10 μg/ml anti pancytokeratin (TebuBio, Le Perray en Yvelines,France). Detection was performed on 12 sections of lymph nodes, which
means that one section every 80 μmwas analyzed.
Tumor studies
Capan-1 transduced cells (2.106) were injected subcutaneously
into NMRInu/nu mice (n = 10). Animals were sacriﬁced 2 weeks
28 A.C. Prats et al. / Microvascular Research 89 (2013) 25–33later and tumors were excised and embedded in OCT for histological
analysis. For rAAV assay, 106 tumor cells were injected 4 weeks
after muscle transduction. Animals were sacriﬁced 28 days later and
tumors and inguinal lymph nodes were excised. Experiments were
performed three times.
Statistical analysis
All statistical analyses were performed with a two-tailed Student's
t-test or ANOVA.
Results
Matrix proteolytic fragment ﬁbstatin cooperates with Chemokine CXCL4L1,
but not with endostatin, to inhibit in vitro angiogenesis
In order to test the effect anti-angiogenic factors combinations,
lentivectors expressing either endostatin, ﬁbstatin, and CXCL4L1 alone
(monocistronic vectors), or combinations of these factors (bicistronic
vectors) were generated (Fig. 1A).
Expression of ﬁbstatin, endostatin, and CXCL4L1 was evaluated by
Western blot in cell pellets and supernatants of Capan-1 cells trans-
duced by the different lentivectors (Figs. 1B–D). Expression of ﬁbstatin,
endostatin or CXCL4L1was easily detected from themonocistronic vec-
tors (Figs. 1B–D). As regards the bicistronic vectors ﬁbstatin–endostatin
and ﬁbstatin–CXCL4L1, they efﬁciently expressed the proteins from the
ﬁrst cistrons, whereas those expressed from the second cistrons were
signiﬁcantly less detectable (Figs. 1B–D). Therefore, two- and three-
timesmore proteinswere loaded on the gel to detect the second cistron
protein. We then produced ﬁbstatin–CXCL4L1 and CXCL4–ﬁbstatin len-
tivirus to evaluate the role of the cistron position in the biological effect
(Figs. 1C,D). The control vectors were non-transduced (NT) cells and
cells transduced by lentivector-GFP (Suppl. Fig. 2).
To evaluate the anti-angiogenic properties of the three molecules,
alone or combined, we tested the ability of conditioned media from
transduced Capan-1 to interfere with FGF2-induced endothelial cell
tubulogenesis assay in Matrigel (Figs. 1E,F). When Capan-1 cellsFig. 2. Effect of endostatin, ﬁbstatin, and CXCL4L1 alone or combined on endothelial cell p
HUVECs. Proliferation of HUVECs following incubation with conditioned media was asses
HUVEC migration using scratch wound healing assay. (C) Brightﬁeld images from FGF2 stimexpressed one anti-angiogenicmolecule,we observed a better inhibition
of in vitro alignment with ﬁbstatin or CXCL4L1 compared to endostatin
(Fig. 1F). Fibstatin–endostatin and ﬁbstatin–CXCL4L1 combinations had
a similar effect as their monocistronic counterpart, probably due to the
poor expression of the second cistron in these cells. In contrast the com-
bination CXCL4L1–ﬁbstatin, shown to co-express the twomolecules efﬁ-
ciently (Figs. 1E,F), exhibited a strong inhibitory effect compared to
CXCL4L1 or ﬁbstatin alone. Surprisingly, when endothelial tubulogenesis
was stimulated with VEGFA, no inhibition was observed with ﬁbstatin
demonstrating the FGF2-speciﬁcity (Suppl. Fig. 3). In this model, no syn-
ergistic effect was observed with ﬁbstatin–endostatin vectors, whereas
ﬁbstatin–CXCL4L1 strongly inhibits tubulogenesis.
Fibstatin and CXCL4L1 exhibit an additive effect to inhibit endothelial cell
migration
To dissect the anti-angiogenic effect of molecules in vitro, we eval-
uated the role of ﬁbstatin, endostatin, and CXCL4L1, alone or combined,
on FGF2-induced survival and migration of HUVECs in vitro. To analyze
proliferation, we incubated HUVECs with conditioned media from
Capan-1 transduced cells and anti-proliferative effects were assessed
by the MTT assay and cell counting assay (Fig. 2A, Suppl. Fig. S4). As
expected, endostatin, ﬁbstatin and CXCL4L1 were able to suppress
endothelial growth. We observed an additional effect on HUVEC survival
of the combinations ﬁbstatin–endostatin and CXCL4L1–ﬁbstatin (Fig. 2A).
The effect of anti-angiogenic molecules on HUVEC migration was
determined by the scratch wound assay (Figs. 2B,C). The three anti-
angiogenic agents inhibited HUVECmigration. However, no beneﬁcial
effect was observed with the combination ﬁbstatin–endostatin. In
contrast, association of CXCL4L1 andﬁbstatin generatedmore inhibition
of HUVEC migration than the molecules alone (Figs. 2B,C). This was
observed for both bicistronic vectors ﬁbstatin–CXCL4L1 and CXCL4L1–
ﬁbstatin.
These data demonstrated that ﬁbstatin and CXCL4L1 was the most
efﬁcient combination to cooperate in vitro to block angiogenesis, and
that this effect is due to inhibition of both proliferation and migration
of endothelial cells (Fig. 2).roliferation and migration. (A) MTT cell proliferation assessment of FGF2-stimulated
sed using an MTT survival assay (*p b 0.01). (B) Quantiﬁcation of the percentage of
ulated HUVEC migration in the presence of conditioned media. *p b 0.01, #p b 0.001.
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tumor growth
To explore the additive effect of the anti-angiogenic molecules on
tumor growth, we used local delivery of anti-angiogenic molecules in
vivo. Capan-1 cells were transduced with the different lentivectors and
subcutaneously injected in nude mice (Fig. 3A). After 7 and 14 days,
tumor bearingmicewere sacriﬁced and primary tumorsweremeasured
and removed for further analysis. We found that ﬁbstatin, endostatin,
and CXCL4L1 are able to inhibit tumor growth and tumor progression
as well as the combinations ﬁbstatin–endostatin and CXCL4L1–ﬁbstatin
(Fig. 3B). However, we did not observe a better anti-tumoral effect with
the CXCL4L1–ﬁbstatin combination compared with ﬁbstatin–CXCL4L1.
Tumor sections were analyzed for angiogenesis by immunohisto-
chemistry (Fig. 3C, Suppl. Fig. 5) and transgene expression in Capan-1
tumors was checked by RT-qPCR (Suppl. Fig. 6). We found that
tumor-induced angiogenesis was substantially suppressed with all
anti-angiogenic factors, alone or combined (Fig. 3C). The effect of the
combination ﬁbstatin–endostatin was similar to that of ﬁbstatin or
endostatin alone,whereas a signiﬁcantly stronger anti-angiogenic effect
was observed for the combination CXCL4L1–ﬁbstatin, as observed for
tubulogenesis in vitro (Figs. 1E–F).
These data showed that CXCL4L1 and ﬁbstatin cooperate to block
tumoral angiogenesis, but that this stronger angiogenesis inhibitionFig. 3. Inhibition of growth and angiogenesis by ﬁbstatin, endostatin, and CXCL4L1 overexpr
and bicistronic anti-angiogenic lentivectors, or by a GFP lentivector as a control were subc
(B, left panel) Cells transduced with anti-angiogenic lentivectors grew at a signiﬁcantly s
(groups of eight animals), with indications of statistical signiﬁcance (*p b 0.001). (B, right
(C) Quantiﬁcation of angiogenesis on cryosection from monocistronic (ﬁbstatin, endostatin
transduced pancreatic tumors (Capan-1). CD31-positive vessels ± SEM per microscopic ﬁehas no beneﬁcial effect on the blockade of tumor growth in the initial
steps of tumor development (2 weeks).
Angiogenesis inhibition by CXCL4L1–ﬁbstatin combination correlates
with blockade of lymph node invasion
The absence of consequence of a stronger angiogenesis inhibition
on tumor growth observed above for the CXCL4L1–ﬁbstatin combina-
tion incited us to analyze tumor draining lymph node invasion. To
target both primary tumor and metastatic loci, we performed rAAVs
expressing mono- or bicistronic vector injections in the mice skeletal
muscle of the leg. rAAVs expressing endostatin, ﬁbstatin, CXCL4L1 or
combinations of these factors were injected in the gastrocnemius and
tibialis muscles four weeks before tumor xenograft (Fig. 4A). Tumoral
angiogenesis was analyzed showing again that the CXCL4L1–ﬁbstatin
combination had the most efﬁcient anti-angiogenic effect (Figs. 4B,C)
compared to monocistronic vectors alone or ﬁbstatin–endostatin
combination. Tumor volume measurement showed, as for the local
delivery, a strong antitumoral effect for all the rAAVs, but as observed
using local delivery with lentivectors, no statistically signiﬁcant addi-
tional inhibitory effect was observed for the CXCL4L1–ﬁbstatin combi-
nation than for each anti-angiogenic factor alone (Fig. 4D).
To evaluate the effect of anti-angiogenic factor combinations on
tumor lymph node invasion, inguinal draining lymph nodes wereession after lentivector transduction. (A) Capan-1 (2.106) cells transduced with mono-
utaneously injected in nude mice. Tumor growth was measured after 7 and 14 days.
lower rate than control cells. The means and standard deviations of sizes are shown
panel) Representative table from day 7 to day 14 lentivector-transduced progression.
, CXCL4L1) and bicistronic (ﬁbstatin–endostatin, and CXCL4L1–ﬁbstatin) lentivector-
ld quantiﬁed in replicate samples. *p b 0.01, #p b 0.001.
Fig. 4. CXCL4L1 and ﬁbstatin cooperate to inhibit angiogenesis. (A) Mice tibialis (20 μL) and gastrocnemius (30 μL) muscles were transduced in vivo using mono- and bicistronic
anti-angiogenic rAAVs. In addition, a bicistronic rAAV expressing the renilla and ﬁreﬂy luciferases was used as a control (Ctrl). Capan-1 (2.106) cells were subcutaneously injected in
nude mice 4 weeks after viral infections. (B) Cryosection of pancreatic cancer (Capan-1) from monocistronic (ﬁbstatin, endostatin, CXCL4L1) and bicistronic (ﬁbstatin–endostatin,
and CXCL4L1–ﬁbstatin) rAAV-transduced bearing mice were immunostained to detect CD31 positive blood vessels (red). Magniﬁcation ×200. Scale bar: 50 μm. (C) CD31-positive
vessels ± SEM per microscopic ﬁeld quantiﬁed in replicate samples. *p b 0.01, #p b 0.001. (D, left panel) tumors from anti-angiogenic rAAV-injected mice grew at a signiﬁcantly
slower rate than control luciferase (Ctrl) rAAV-injected mice. The means and standard deviations of sizes are shown (groups of 10 animals), with indications of statistical signiﬁ-
cance (*p b 0.001). (D, right panel) Representative table from day 14 to day 28 tumor progression.
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cytokeratin positive tumor cells (Fig. 5A). We observed an inhibition
of tumor cell invasion with all anti-angiogenic factors, alone or com-
bined (Fig. 5A). However, we found a few clusters of cytokeratin-
positive tumor cells in ﬁbstatin–endostatin group, whereas no tumor
cell was detected in CXCL4L1–ﬁbstatin mice (Fig. 5B).
To determine a beneﬁcial effect of the CXCL4L1–ﬁbstatin combina-
tion compared to CXCL4L1 alone, wemeasured the level of expression
of anti-angiogenic factors by Western blot on muscle protein extracts.
This revealed a lower expression of anti-angiogenic factor expressed by
the bicistronic AAVs, than by the monocistronic AAVs (Figs. 5C–F). In
particular, CXCL4L1 and ﬁbstatin expression were about 3 folds and
10 folds less expressed (Fig. 5F). These studies clearly indicated that
CXCL4L1 associated with ﬁbstatin is able to completely abolish tumorinvasion at a lower dose than when administrated alone suggesting a
synergistic effect of ﬁbstatin and CXCL4L1, which is not observed for
ﬁbstatin and endostatin.
Fibstatin and CXCL4L1 inhibit tumor lymphangiogenesis
Lymphangiogenesis plays a crucial role in tumor dissemination to
the lymph nodes. Recent studies have shown that endostatin inhibits
both tumor angiogenesis and lymphangiogenesis, however nothing
has been reported for ﬁbstatin or CXCL4L1 (Brideau et al., 2007; Ou
et al., 2011). To analyze the effect of these molecules, alone or com-
bined, on tumor lymphangiogenesis in vivo, lentivector-transduced
Capan-1 cells were subcutaneously implanted into immunodeﬁcient
mice for two weeks. Tumors were removed and lymphangiogenesis
Fig. 5. Inhibition of tumor invasion using combination of anti-angiogenic molecules. (A, B) Tumor invasion to the sentinel lymph nodes was evaluated by cytokeratin
immunodetection. (A) Cryosection of inguinal sentinel lymph nodes from ﬁbstatin–endostatin and CXCL4L1–ﬁbstatin rAAV-injected tumor bearing mice were immunostained
to detect cytokeratin positive tumor cells (green). (A) magniﬁcation ×4 upper panel, ×200 bottom panel, scale bar: 50 μm. (B) Representative table of tumor cells inﬁltrated
lymph nodes (10 mice per group). (C, D) Following tibialis and gastrocnemius muscles injections with monocistronic (ﬁbstatin or endostatin) or bicistronic (ﬁbstatin–endostatin)
rAAVs, muscle extracts were analyzed by Western blot with anti-HA antibodies eight weeks after vector injection (C) and signal was quantiﬁed (D). (E, F) Following tibialis and
gastrocnemius muscles injections with monocistronic (ﬁbstatin and CXCL4L1) or bicistronic (CXCL4L1–ﬁbstatin) rAAVs, muscle extracts were analyzed by Western blot with
anti-HA and anti-CXCL4L1 antibodies eight weeks after vector injection (E) and signal was quantiﬁed (F).
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(Garmy-Susini et al., 2007). We found that tumor-induced lymphangi-
ogenesis was substantially suppressed using monocistronic as well as
bicistronic lentivectors (Fig. 6A). Interestingly, ﬁbstatin and CXCL4L1
were more anti-lymphangiogenic than endostatin. In contrast to the
data observed on angiogenesis, the combinations of molecules did not
increase their effect on lymphangiogenesis.
When Capan-1 pancreatic carcinoma tumor cells were implanted
subcutaneously in AAV-transduced mice, a strong inhibition of tumor
lymphangiogenesis was observed with all the vectors, especially with
the ﬁbstatin. No better beneﬁcial effect was detected using bicistronic
versus monocistronic vectors (Figs. 6B–C). Nevertheless, as shown in
Figs. 5C–F, we found a similar inhibitory effect of bicistronic vectors
with lower amount of proteins, suggesting a cooperation of the mole-
cules in the inhibition of lymphangiogenesis.These data revealed ﬁbstatin and CXCL4L1 as efﬁcient anti-
lymphangiogenic factors able to act upon local as well as distant
delivery.
Discussion
This study reveals ﬁbstatin and CXCL4L1 as new endogenous
inhibitors of tumor lymphangiogenesis and metastasis. Furthermore,
the combined administration of ﬁbstatin and CXCL4L1 shows that
they cooperate in the inhibition of tumoral angiogenesis. Interestingly,
combined administration of the two molecules shows no beneﬁcial
effect on tumor growth,whereas it allows them to block tumor invasion
in lymph node at lower doses.
Angiogenesis inhibitors for the treatment of cancer aim at depriving
a tumor from developing the blood vessels and capillaries needed for
Fig. 6. Combination of ﬁbstatin, endostatin and CXCL4L1 strongly inhibit tumor lymphangiogenesis. (A) Cryosection from pancreatic tumor (Capan-1) transduced with
monocistronic (ﬁbstatin, endostatin, CXCL4L1) or bicistronic (ﬁbstatin–endostatin, CXCL4L1–ﬁbstatin) lentivector were immunostained to detect Lyve-1 positive lymphatic vessels
and quantiﬁed. Lyve-1-positive vessels ± SEM per microscopic ﬁeld quantiﬁed in replicate samples. *p b 0.01, #p b 0.05. (B) Cryosection of pancreatic tumors (Capan-1) frommice
treated with monocistronic (ﬁbstatin, endostatin, CXCL4L1) or bicistronic (ﬁbstatin–endostatin, CXCL4L1–ﬁbstatin) rAAV were immunostained to detect Lyve-1 positive lymphatic
vessels (green). Magniﬁcation ×200. Scale bar: 50 μm. (C) Lyve-1-positive vessels ± SEM per microscopic ﬁeld quantiﬁed in replicate samples. *p b 0.01.
32 A.C. Prats et al. / Microvascular Research 89 (2013) 25–33further growth (Kerbel and Folkman, 2002). Nevertheless, progression-
free survival beneﬁts from approved antiangiogenic drugs remain
modest. Recent studies have shown that additionally to angiogenesis,
lymphangiogenesis develops in primary tumors or in the peritumoral
space and promotes lymphatic metastasis (Avraamides et al., 2008;
Tammela and Alitalo, 2010). We show here that the anti-angiogenic
factors used in our study exhibit both anti-angiogenic and anti-
lymphangiogenic effects. However, we show that ﬁbstatin and
CXCL4L1 are stronger inhibitors of lymphangiogenesis than endostatin,
which correlateswith the inhibition of lymph node invasion using these
molecules. This supports the crucial role of lymphangiogenesis in tumor
invasion and underlines the importance of developing treatments
against cancer that target lymphangiogenesis in addition to angiogene-
sis, to block metastasis dissemination.
The use of combined therapeutics has appeared for several years as a
new concept to counteract the tumor cell ability to escape an anti-
angiogenic treatment (Byers and Heymach, 2007). The ﬁrst combina-
tion to show its efﬁciency has been association of endostatin and
angiostatin, either by plasmid transfection or viral vector transduction,
or by using endostatin–angiostatin chimer (Campochiaro, 2011, 2012;
Ponnazhagan et al., 2004). Such a combination appears as a promising
therapeutic for ocular neovascularization diseases as well as for cancertherapeutics (Foy et al., 2011; Kim and Park, 2005). Another example
of efﬁcient combined treatment is the association of HER-2 and VEGF
peptide mimics, which provides greater efﬁcacy than individual treat-
ments on breast tumor angiogenesis and growth (Foy et al., 2011).
However the beneﬁt of combining anti-angiogenic factors cannot be
generalized to any molecule association. A previous study has reported
the absence of beneﬁt of combined delivery of anti-angiogenic agents
p53, GM-CSF and angiostatin, leading to the conclusion that they pro-
duce their anti-metastatic activity through a common anti-angiogenic
pathway (Liu et al., 1999). Indeed our data also show that the coopera-
tive effect is dependent on the nature of the combined molecules: we
observe no cooperation between two extracellular matrix proteolysis
fragments, endostatin and ﬁbstatin, whereas the combination of
ﬁbstatin with the chemokine CXCL4L1 demonstrates its cooperative
efﬁcacy between inhibitors targeting at the same time tyrosine kinase
and GPCR receptors (Liu et al., 1999). This strongly correlates with the
hypothesis of Liu et al. (1999): anti-angiogenic factors cooperate if
they act on different anti-angiogenic pathways.
Anti-cancer therapeutics by gene delivery is used in many clinical
trials. According to the data of the Journal of Gene Medicine (http://
www.abedia.com/wiley), 1155 gene therapy clinical trials against
cancer are ongoing in 2012, which represents 64.7% of all clinical
33A.C. Prats et al. / Microvascular Research 89 (2013) 25–33trials in gene therapy. However, although the concept of combined
therapeutic efﬁcacy in cancer treatment is more and more accepted,
very little data are available reporting the use of IRES-based vectors to
co-express therapeutic molecules. A bicistronic rAAV coding angiostatin
and endostatin with the encephalomyocarditis virus (EMCV) IRES has
been shown to promote a long-term efﬁcacy of transgene expression
and antitumoral effect in a model of human ovary cell line
(Ponnazhagan et al., 2004). However, this report does not mention the
effect of the bicistronic vector on angiogenesis, lymphangiogenesis or
metastasis dissemination. We have previously validated the principle
of IRES-based vectors for gene therapy of limb ischemia in a mouse
model, by showing that a plasmid containing the FGF1 IRES (very active
inmuscle) and co-expressing FGF2 and Cyr61, allows thesemolecules to
act in synergy to promote therapeutic angiogenesis (Delluc-Clavieres
et al., 2008; Rayssac et al., 2009). Here we validate the use of IRES-
based vectors, i.e. rAAVswith the FGF1 IRES, for anti-(lymph)angiogenic
and anti-metastatic therapeutics.
Pancreatic adenocarcinoma is characterized by local invasion of
adjacent structures and early metastasis to the lymph nodes and the
liver (Rupp and Linehan, 2009). Because of difﬁculties in early diagnosis
and effective treatment, pancreatic cancer is often lethal, and particularly
requires the development of new therapeutics able to target metastases
(Gordis and Gold, 1984). Although little information is available about
the efﬁciency of anti-angiogenic therapy in pancreas adenocarcinoma,
it has been clearly shown that induction of angiogenesis and lymphangi-
ogenesis facilitates the progression of pancreatic cancer (Cui et al., 2011;
Mulder et al., 2010). Here we observe a strong inhibition of Capan-1
tumor angiogenesis and lymphangiogenesis with an optimal effect of
the combination CXCL4L1–ﬁbstatin. More importantly, we demonstrate
that the anti-(lymph)angiogenic rAAVs clearly inhibit tumor metastasis
to the lymph nodes with the synergistic effect of CXCL4L1–ﬁbstatin on
both macro- and micro-metastases.
Conclusion
In the light of our study, CXCL4L1 and ﬁbstatin thus appear as new
attractive candidates to be used in combination for the treatment of
cancer and the IRES-based vector gene therapy represents a promising
approach in the clinical setting to suppress the spread of tumors
through the lymphatic system. Furthermorewe demonstrate that intra-
muscular delivery of therapeutic molecules using rAAVs is deﬁnitively
efﬁcient to target both primary tumor and metastasis and provides a
new therapeutic approach inhighlymetastatic cancers such as pancreatic
cancer.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.mvr.2013.05.005.
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